Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John de Groot

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Investigational New Drugs|November 13, 2014
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastomaDavid Schiff, Santosh Kesari, John de Groot, et al.
Oncotarget|November 20, 2019
Pre-surgical connectome features predict IDH status in diffuse gliomasShelli R Kesler, Rebecca A Harrison, Melissa L Petersen, et al.
Molecular Cancer Therapeutics|April 14, 2007
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivoTa-Jen Liu, Tiffany LaFortune, Toshiyuki Honda, et al.
Current Neurology and Neuroscience Reports|April 5, 2024
Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for GlioblastomaKazim H Narsinh, Edgar Perez, Alexander F Haddad, et al.
Oncotarget|March 1, 2018
Ependymomas overexpress chemoresistance and DNA repair-related proteinsSherise D Ferguson, Shouhao Zhou, Joanne Xiu, et al.
Neuro-Oncology Advances|March 3, 2026
Focused ultrasound-enhanced cell therapy for brain tumors: Summary of roundtable discussionsFrederic Padilla, Costas Arvanitis, Catherine M Bollard, et al.
Neuro-Oncology Advances|October 25, 2021
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastomaShiao-Pei Weathers, Julie Rood-Breithaupt, John de Groot, et al.
Journal of Neurosurgery|January 24, 2025
Focused ultrasound therapy as a strategy for improving glioma treatmentJacob S Young, Alexa Semonche, Ramin A Morshed, et al.
Neuro-Oncology|April 4, 2017
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapyTiffany R Hodges, Martina Ott, Joanne Xiu, et al.
Journal of Neuro-Oncology|June 25, 2025
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastomaPushan Dasgupta, Heather Lin, Gayatri Kumar, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Investigational New Drugs|November 13, 2014
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastomaDavid Schiff, Santosh Kesari, John de Groot, et al.
Oncotarget|November 20, 2019
Pre-surgical connectome features predict IDH status in diffuse gliomasShelli R Kesler, Rebecca A Harrison, Melissa L Petersen, et al.
Molecular Cancer Therapeutics|April 14, 2007
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivoTa-Jen Liu, Tiffany LaFortune, Toshiyuki Honda, et al.
Current Neurology and Neuroscience Reports|April 5, 2024
Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for GlioblastomaKazim H Narsinh, Edgar Perez, Alexander F Haddad, et al.
Oncotarget|March 1, 2018
Ependymomas overexpress chemoresistance and DNA repair-related proteinsSherise D Ferguson, Shouhao Zhou, Joanne Xiu, et al.
Neuro-Oncology Advances|March 3, 2026
Focused ultrasound-enhanced cell therapy for brain tumors: Summary of roundtable discussionsFrederic Padilla, Costas Arvanitis, Catherine M Bollard, et al.
Neuro-Oncology Advances|October 25, 2021
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastomaShiao-Pei Weathers, Julie Rood-Breithaupt, John de Groot, et al.
Journal of Neurosurgery|January 24, 2025
Focused ultrasound therapy as a strategy for improving glioma treatmentJacob S Young, Alexa Semonche, Ramin A Morshed, et al.
Neuro-Oncology|April 4, 2017
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapyTiffany R Hodges, Martina Ott, Joanne Xiu, et al.
Journal of Neuro-Oncology|June 25, 2025
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastomaPushan Dasgupta, Heather Lin, Gayatri Kumar, et al.
Pageof 9